Viridion Therapeutics

Preventing Cancer Recurrence
Through Immune Reprogramming.

For most solid tumor patients, the first treatment is not the problem — recurrence is. Viridion is built on a single scientific premise: lasting remission requires reprogramming the tumor microenvironment, not just shrinking the tumor.

3

Therapeutic molecules / construct

60–80%

Recurrence within 3–5 years

3

Independent mechanisms

0

Approved combined therapies

Yale-origin science · CARG-2020 exclusively licensed from CaroGen Corporation (Yale spin-off) · AVIDIO™ VLV platform.

The Problem

Why Cancer Comes Back.

After surgery, chemotherapy, or radiation, residual cancer cells often persist in a microenvironment that actively shields them from immune attack. This suppression operates through three simultaneous mechanisms — and no approved therapy addresses all three at once.

Immune Exhaustion

Tumors upregulate PD-L1, switching off T-cells that would otherwise attack residual
disease.

Tumor-Promoting Inflammation

The IL-17 pathway creates a chronic inflammatory shield that protects surviving cancer cells from immune attack.

Immune Exclusion

Suppressive signaling physically prevents T-cells from entering the tumor microenvironment — rendering even activated immune cells ineffective.

No Existing Solution

Current immunotherapies target a single immune axis. Durable control requires addressing all three mechanisms simultaneously.

Our Approach

Multifunctional Immune Reprogramming.

Viridion's science was developed at Yale School of Medicine and centers on a multifunctional immunotherapy approach that engages all three suppression mechanisms in a single therapeutic construct. Rather than targeting one pathway and hoping for the best, our lead candidate CARG-2020 simultaneously activates anti-tumor immunity, blocks tumor-promoting inflammation, and silences immune checkpoints.

IL-12

Activates Immunity

Converts suppressed immunity to an active anti-tumor T-cell response

IL-17

Blocks Inflammation

Removes the inflammatory shield protecting residual tumors

PD-L1

Silences Checkpoints

Prevents tumors from hiding via checkpoint escape

The result is a converted tumor microenvironment — one that supports durable, systemic immune memory rather than enabling recurrence.

Scientific Foundation

Yale-Origin Science. Peer-Reviewed Validation.

Viridion's approach is built on more than a decade of research from Yale School of Medicine, supported by peer-reviewed publications and validated across multiple preclinical models.

VLV platform was originally discovered by former professor John Rose at Yale School of Medicine and licensed to CaroGen for the development of HBV immunotherapy products. CARG-2020 was developed by CaroGen scientists in collaboration with Professor Gil Mor at Wayne State University and Dr. Kepeng Wang at the University of Connecticut Medical School.

Published in Cancer Immunology Research (2023), Acta Pharmaceutica Sinica B (2024), and Scientific Reports (2025).

The proprietary virus-like vesicle platform enables co-expression of multiple therapeutic payloads from a single construct.

Therapeutic activity demonstrated across ovarian, melanoma, and triple-negative breast cancer models without construct modification.

Explore the Lead Program.

See how CARG-2020 translates Viridion's science into a first-in-class therapeutic candidate.

Or review the preclinical validation data